Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) today announced receipt of approval from the Ministry of Health, Labor and Welfare (MHLW) for the anticancer agent/antimicrotubule binding anti-CD79b monoclonal antibody Polivy intravenous infusion (polatuzumab vedotin (genetical recombination) for an additional indication of treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Polivy plus R-CHP has been approved as a new treatment option, the first in 20 years, for untreated diffuse large B-cell lymphoma (DLBCL) following the approval for relapsed or refractory DLBCL last year
Polatuzumab vedotin was developed by Swiss pharma giant Roche (ROG: SIX) – which owns 62% of Chugai - using Seagens’ (Nasdaq: SGEN) ADC technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze